1. HBW Insight
  2. >>Ingredients & Safety
  3. >>Cannabis/CBD

Legislating US Regulatory Pathway For Cannabinoids ‘Not End of The World’ – Gottlieb

 
• By Eileen Francis

Former FDA commissioner says legislative carve-out for a regulatory pathway for cannabinoids is a better option than a rulemaking, which could take five years and “may not even work.” Cannabinoids market is “well far ahead of where the regulation is,” he says.

Industry stakeholders and lawmakers opposed to legislating lawful use of hemp-derived cannabinoids in dietary should consider the amount of time needed for a rulemaking, says former US Food and Drug Administration head Scott Gottlieb.

“You don’t like to do it, you don’t like to carve ingredients or drug substances out of the regulatory scheme,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cannabis/CBD

EFSA Suggests 2mg Daily CBD Limit, Cannot Establish Safe Intake For Under 25s

 
• By David Ridley

EFSA is consulting on a provisional CBD safe dose of 2mg for a 70kg adult and has stated that the safety of CBD cannot be established for individuals under 25 years of age, pregnant or lactating women, and those on existing medications.

French Agency Proposes Effective EU Ban On CBD In Foods And Cosmetics

 
• By David Ridley

France's food safety regulator ANSES is proposing a reproductive toxicity category 1B classification for CBD under the EU's CLP regulation, which would mean an effective ban on CBD in cosmetics and foods. However, French hemp industry association UIVEC hopes that new evidence coming out of a European Commission review will put the issue to bed before it gets that far.

Senate Hemp Regulation Bill’s Broad Prohibition On Synthetics In Supplements Has Industry Attention

 
• By Malcolm Spicer

Provision in Wyden and Merkley’s “Cannabinoid Safety and Regulation Act” referencing FDA authority outside hemp-derived ingredients could provide agency with needed authority to force from the market products labeled as supplements but containing drugs or eliminate the use of many safe ingredients in supplements.

Senate Hemp Regulation Bill Offers Option To House’s Blanket Limit On Levels Of All THCs

 
• By Malcolm Spicer

Democrats Wyden and Merkley author Cannabinoid Safety and Regulation Act to limit sales to consumers 21 and older and authorize FDA to order recalls and impose bans on cannabis products with dangerous chemicals or additives. It also would establish regulatory structure for using cannabinoids found naturally in hemp and allowing “semi-synthetic” ingredients while prohibiting artificial or fully synthetic cannabinoids.

More from Ingredients & Safety

German Quaternary Wastewater Treatment Cost Estimates ‘Not Realistic’

 
• By David Ridley

Updating wastewater treatment facilities in Germany will cost almost three times more than the German Association of Local Public Utilities (VKU) has predicted, according to a Pharma Deutschland analysis.

GSCF: ‘No One Size Fits All’ Solution To Tricky Sustainable Blister Pack Challenge

 
• By David Ridley

A series of research papers recently published by the Global Self-Care Federation indicate that industry will need to be pragmatic about alternatives to PVC in medicine blister packs.

EFSA: ‘A Dose Of Estragole Without A Harmful Effect Cannot Be Established’

 
• By David Ridley

Dietary supplements containing estragole may have to be removed from the European Union market due to carcinogenic risk, according to a draft scientific opinion from EFSA that is currently out for consultation.